Molecular Characterization of Mycobacterium ulcerans DNA Gyrase and Identification of Mutations Reducing Susceptibility to Quinolones In Vitro

Hyun Kim,a Shigetarou Mori,a Tsuyoshi Kenri,a Yasuhiko Suzukib,c

aDepartment of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan
bDivision of Bioresources, Hokkaido University International Institute for Zoonosis Control, Sapporo, Japan
cInternational Collaboration Unit, Hokkaido University International Institute for Zoonosis Control

ABSTRACT Buruli ulcer disease is a neglected necrotizing and disabling cutaneous tropical illness caused by Mycobacterium ulcerans. Fluoroquinolone (FQ), used in the treatment of this disease, has been known to act by inhibiting the enzymatic activities of DNA gyrase. However, the detailed molecular basis of these characteristics and the FQ resistance mechanisms in M. ulcerans remains unknown. This study investigated the detailed molecular mechanism of M. ulcerans DNA gyrase and the contribution of FQ resistance in vitro using recombinant proteins from the M. ulcerans subsp. shinshuense and Agy99 strains with reduced sensitivity to FQs. The IC$_{50}$ of FQs against Ala91Val and Asp95Gly mutants of M. ulcerans shinshuense and Agy99 GyrA subunits were 3.7- to 42.0-fold higher than those against wild-type (WT) enzyme. Similarly, the quinolone concentrations required to induce 25% of the maximum DNA cleavage (CC$_{25}$) was 10- to 210-fold higher than those for the WT enzyme. Furthermore, the interaction between the amino acid residues of the WT/mutant M. ulcerans DNA gyrase and FQ side chains were assessed by molecular docking studies. This was the first elaborative study demonstrating the contribution of mutations in M. ulcerans DNA GyrA subunit to FQ resistance in vitro.

KEYWORDS Buruli ulcer disease, DNA gyrase, fluoroquinolone resistance, Mycobacterium ulcerans, supercoiling assay, molecular docking study

Buruli ulcer disease (BUD) is an emerging chronic ulcerating illness caused by environmental Mycobacterium, Mycobacterium ulcerans, which primarily affects the skin, subcutaneous tissue, and occasionally bones. It is recognized by the World Health Organization (WHO) as a neglected tropical disease (1) and is the third most frequent skin mycobacterial disease worldwide after leprosy and tuberculosis (2, 3). BUD is gradually increasing with approximately 2,000 to 5,000 new annual reported cases (4, 5). The cases have been reported in over 33 countries worldwide, primarily in tropical and subtropical regions (4), such as West Africa, Central Africa, South Africa, and the Western Pacific countries (6–9). The reasons for increases in the past few years have not been understood (10–12).

The mode of transmission of M. ulcerans is not known although it is suggested to be through direct inoculation of the skin or subcutaneous tissue (13). M. ulcerans produces mycolactone, an immunomodulatory macrolide toxin which is the main pathogenic factor of BUD. M. ulcerans infections result in painless ulcers with undermined edges and necrotic sloughing which often affects the upper or lower limbs and the face (14). Recently, drug therapy against M. ulcerans has been administered through anti-mycobacterial antibiotics, including rifampicin-based combinations with either streptomycin, amikacin, or clarithromycin (15–17). Early and nonsevere stages of BUD can be treated with an 8-week regimen of rifampicin (10 mg/kg orally, once daily) combined with clarithromycin (7.5 mg/kg per body weight, 10.1128/aac.01902-21
twice daily), streptomycin (15 mg/kg intramuscularly, once daily), fluoroquinolone (FQ) or other antibiotics (15–19).

FQ is effective against M. ulcerans in vitro and in vivo (16, 20–22). Evidence exists that DNA topoisomerase II is the therapeutic target of the drug. Most eubacteria have two DNA topoisomerases II (DNA gyrase and DNA topoisomerase IV), which are essential for efficient DNA replication and transcription (23, 24), and among a few clinically validated targets for antibiotic therapies (25, 26). Remarkably, M. ulcerans expresses only DNA gyrase (27, 28) from a gyrB linked gyrA contig in the complete genome and this enzyme is the sole target of FQs (26). The catalytically active mycobacterial DNA gyrase has a Gyra,GyrB3 tetrameric structure (29) and is an ATP-dependent enzyme that transiently cleaves and unwinds double-stranded DNA to catalyze DNA negative supercoiling (30, 31). However, the detailed molecular mechanism of M. ulcerans DNA gyrase and the mechanisms of FQ resistance were not determined.

This study aimed to determine the functional analysis of M. ulcerans DNA gyrase activities in vitro from M. ulcerans shinshuense and Agy99 strains. DNA gyrase subunits of both strains were expressed and purified as a recombinant protein and its activity was investigated in vitro via supercoiling assays. In addition, specific structural interactions between wild-type (WT)/mutant M. ulcerans DNA gyrase and FQs were identified via molecular docking. Because the FQs tested had limited activity against the FQ-resistant M. ulcerans DNA gyrase, the development and design of novel antibiotics against BU, are recommended.

RESULTS

Expression and purification of recombinant M. ulcerans DNA gyrase. The entire gene sequences of WT gyrA and gyrB from M. ulcerans shinshuense and Agy99 strains and mutant gyrA (Ala91Val and Asp95Gly) were amplified and inserted into expression vector pColdI- on downstream of the cspA promoter to heterologous express N-terminal hexahistidine-tagged gyrase subunits (Table 1). Molecular docking predicted that the his6-tag was located away from the FQ binding site of the M. ulcerans DNA GyrA (Fig. 1A) and GyrB (unpublished data) subunit suggesting that it will not interfere with GyrA activity. Expressed WT/mutant Gyra and GyrB subunits were purified to homogeneity using a two-step column chromatographic procedure described in Materials and Methods with the expected molecular masses of Gyra (93 kDa) and GyrB (76 kDa) subunits determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 1B). All recombinant DNA gyrase subunits were obtained at high purity (>95%) in milligram amounts. Contaminating Escherichia coli (E. coli) topoisomerase activity was denied by the lack of supercoiling activities either only with M. ulcerans Gyra or GyrB subunit (Fig. 2; lanes 2 and 3 for M. ulcerans shinshuense; lanes 6 and 7 for M. ulcerans Agy99).

Supercoiling activities of WT and mutant M. ulcerans DNA gyrase. The supercoiling activities of each DNA gyrase subunit were investigated by varying the subunit concentration

### Table 1: List of oligonucleotides

| Primer no. | Sequence of oligonucleotide (positions) | Comments |
|------------|----------------------------------------|----------|
| K-116      | 5′—CCATATGACAGACACGAC—3′               | M. ulcerans gyrA Fw |
| K-121      | 5′—GGCTCGACGCACTAGTGTGAGCTGTCGAACGAG—3′ | M. ulcerans gyrA Rv |
| K-117      | 5′—GAACCCGACGTCGAATG—3′               | For gyrA sequence |
| K-118      | 5′—CCGGTGGGCCCTGCG—3′                 | For gyrA sequence |
| K-119      | 5′—CGTCGACAAGCAGCAG—3′               | For gyrA sequence |
| K-120      | 5′—CGGGCGCCAGCGAG—3′                  | For gyrA sequence |
| K-122      | 5′—CATATGACTGAGACGCCG—3′              | M. ulcerans gyrB Fw |
| K-149      | 5′—CGGAGCTTCTAAACAGCAGACAGCC—3′      | M. ulcerans gyrB Rv |
| K-123      | 5′—CGACTGCGAAGTGACC—3′               | For gyrB sequence |
| K-124      | 5′—CGGATCGGTCGACA—3′                  | For gyrB sequence |
| K-125      | 5′—CGGCAAAGTAGGCCC—3′                 | For gyrB sequence |
| K-184      | 5′—CGCGACCGGAGTGCTGAGTTCATGAC—3′     | M. ulcerans Ala91Val Fw |
| K-185      | 5′—GCTCAGAGTACGCCATCAGTGCACGAG—3′    | M. ulcerans Ala91Val Rv |
| K-182      | 5′—CGGGTGATCGTACCCAGACCTTGGTGCGG—3′  | M. ulcerans Asp95Gly Fw |
| K-183      | 5′—CGCACCAAGTGAGATCGAGACGCACG—3′     | M. ulcerans D95Gly Rv |

*Italic: restriction enzyme site; underline: position of point mutation.*
Three micromolar of WT and mutants *M. ulcerans* shinshuense GyrA and GyrB subunits (Fig. 3A and C), or 3 μM WT and mutants *M. ulcerans* Agy99 GyrA and GyrB (Fig. 3B and D) converted 100% of 0.3 μg of relaxed pBR322 plasmid DNA substrate to its supercoiled form. This subunit concentration was used for all subsequent enzyme assays.

The supercoiling activity of *M. ulcerans* DNA gyrase was ATP-dependent (Fig. 2, lane 4 and 8) and required the combination of GyrA and GyrB (Fig. 2, lane 1 and 5). Mutant GyrA (Ala91Val and Asp95Gly) had DNA supercoiling activity in the presence of WT GyrB (data not shown). Furthermore, we found that the optimum temperature of *M. ulcerans* DNA gyrase was 30 to 37°C and its activity decreased at 40°C (Fig. 4) and is similar to those of the *Mycobacterium leprae* DNA gyrase from our previously reported (32). Therefore, all other assays were performed at 30°C.
Inhibitory effect of FQs against *M. ulcerans* WT and mutant DNA gyrases. The inhibitory effect of FQs ciprofloxacin (CIP), moxifloxacin (MOX), and levofloxacin (LVX) on each WT and mutant (*M. ulcerans shinshuense* and Agy99) DNA gyrase were elucidated using the DNA supercoiling assay (Fig. 5). IC_{50} values were ordered from low to high (Table 2), with the structure of each FQ shown in Table 2A to D. IC_{50}s from both strains of DNA gyrase were comparable to that observed (Table 2). The mutant DNA gyrase was highly resistant to inhibition by CIP and LVX (Fig. 5 and Table 2) with IC_{50}s of 320 \mu g/mL, whereas the *M. ulcerans* shinshuense and Agy99 WT gyrase were 11.80 and 7.52 \mu g/mL, respectively (Table 2).

To examine the effects of FQ on cleavage complex formation by *M. ulcerans* recombinant DNA gyrases, cleavage activities were performed in which supercoiled pBR322 DNA was incubated with WT or mutant DNA gyrases in the presence or absence of increasing concentrations of FQs. The representative results of cleavage activity using LVX against *M. ulcerans* Agy99 DNA gyrase were shown in Fig. 6, and Table 2 presents the CC_{25} of CIP and MOX. The CC_{25} of FQs for WT DNA gyrase ranged from 0.038 to 1.53 \mu g/mL, while those for the mutant DNA gyrases ranged from 1.04 to 67.68 \mu g/mL (Table 2).

**Binding mode between DNA gyrase and FQs.** The detailed interaction between WT/mutant *M. ulcerans* shinshuense DNA gyrase and FQs was determined via molecular docking using molecular operating environment (MOE) software (Fig. 7). The representative molecular docking results of CIP or MOX against *M. ulcerans* WT shinshuense and mutants DNA gyrase are shown in Fig. 7, whereas the Agy99 DNA gyrase data are not shown because the amino acid sequence has 95% homologous identity and FQ binding site was 100% (Fig. S1). The docking score and root mean square deviation (RMSD) between CIP and WT DNA gyrase, or GyrA mutants (Ala91Val/Asp95Gly) were 26.3081 and 4.02 Å, or 26.3239/26.4195 and 3.48/4.04 Å, respectively (Fig. 7C). Meanwhile, the docking score and RMSD between MOX and WT DNA gyrase, or GyrA mutants (Ala91Val/Asp95Gly) were −8.0615 and 2.15 Å, or −8.0615 and 2.15 Å, respectively.
A hydrogen-bonding network between the side chains of CIP and the amino acids of WT GyrA subunit: Ala91 (2.53 and 2.73 Å), Asp95 (2.94 and 2.82 Å), and Thr96 (2.44 Å) was observed (Fig. 7A). However, the interaction of CIP with the Asp95Gly GyrA mutant was not observed (Fig. 7A) which correlated with the significantly higher IC₅₀ value of the Asp95Gly GyrA mutant compared with that of the WT and Ala91Val mutants. Similarly, the binding mode of MOX and distance were observed (Fig. 7B). Based on the molecular docking results, these amino acid residues in the GyrA subunit may play an important role in the interaction between \textit{M. ulcerans} DNA gyrase and FQs.

**DISCUSSION**

Although the inhibitory effects of FQs against BU₀ are known \textit{in vitro} and \textit{in vivo} (16, 20–22), the molecular details between \textit{M. ulcerans} DNA gyrase and FQs interactions are not understood.

Nakanaga et al. (32) reported the drug susceptibility test of \textit{M. ulcerans} shinshuense and Agy99 strain. Their findings demonstrate the differences in MIC values between \textit{M. ulcerans} shinshuense (0.25 μg/mL) and Agy99 (8.0 μg/mL) strains for LVX. Although the precise molecular mechanism contributing to this drastic difference in the MIC values of the two \textit{M. ulcerans} strains has not been elucidated, it is speculated that these differences may be due to the drug efflux pump which may pump out the LVX, thereby raising the increased MIC value (33). In this regard, we are focused on the more detailed mechanism of FQ resistance against two strains \textit{in vitro} using a bacterial recombinant system. Furthermore, we investigated the amino acid substitutions at positions 91 and 95 on the GyrA subunit from both \textit{M. ulcerans} strains which is equivalent to positions 90 and 94 in \textit{M. tuberculosis} known to contribute to FQ resistance (32, 34, 35). The resistance of mutant DNA gyrase to FQs was demonstrated at the molecular level using purified recombinantly expressed subunits by supercoiling and inhibition assays.

To measure the absolute concentration for DNA gyrase activity, the concentration of purified DNA gyrase subunits was calculated by two steps, because the DNA gyrase activity required the 1:1 ratio of GyrA and GyrB subunit. The first step was a general calculator system from the Qubit assay kit (data not shown), and the second step was a concentration-dependent supercoiling assay with variable concentrations of GyrA or GyrB.
subunits (Fig. 3). The optimum concentrations of GyrA and GyrB subunits (1:1 ratio) were decided. The WT M. ulcerans Agy99 and mutants (including M. ulcerans shinshuense mutants) were each 3 μM of GyrA and GyrB subunit (Fig. 3). However, WT M. ulcerans shinshuense GyrA and GyrB subunits used to determine the absolute enzyme activity were 3 μM and 1 μM, respectively (Fig. 3A). This estimation was based on the erroneous first step, which yielded an incorrect result for the WT M. ulcerans GyrB subunit. Hence, it was rectified to 3 μM WT M. ulcerans shinshuense GyrA and GyrB (Fig. 3A).

### TABLE 2 The results of inhibition assay and structure of FQs

|                  | M. ulcerans shinshuense | M. ulcerans Agy99 |
|------------------|-------------------------|-------------------|
|                  | IC50 (μg/mL)            | CC25 (μg/mL)      |
| WT Ala91Val     | 11.80 ± 2.05            | 319.5             |
| Asp95Gly        | 7.52 ± 0.58             | >320              |
| WT Ala91Val Asp95Gly | >320                   | 53.83 ± 4.81      |

|                  | M. ulcerans shinshuense | M. ulcerans Agy99 |
|------------------|-------------------------|-------------------|
|                  | IC50 (μg/mL)            | CC25 (μg/mL)      |
| WT Ala91Val     | 0.10 ± 0.1              | 0.32 ± 0.1        |
| Asp95Gly        | 3.69 ± 1.0              | 17.95 ± 1.1       |
| WT Ala91Val Asp95Gly | >320                   | 0.32 ± 0.1        |

|                  | MOX                     |                  |
|------------------|-------------------------|------------------|
|                  | IC50 (μg/mL)            | CC25 (μg/mL)      |
| WT Ala91Val     | 14.65 ± 1.52            | 9.65             |
| Asp95Gly        | 73.43 ± 9.65            | >320             |
| WT Ala91Val Asp95Gly | 2.19 ± 0.29            | 79.08 ± 10.07    |

|                  | MOX                     |                  |
|------------------|-------------------------|------------------|
|                  | IC50 (μg/mL)            | CC25 (μg/mL)      |
| WT Ala91Val     | 10.50 ± 1.32            | 264.03 ± 25.95   |
| Asp95Gly        | 13.29 ± 1.40            | >320             |

|                  | LVX                     |                  |
|------------------|-------------------------|------------------|
|                  | IC50 (μg/mL)            | CC25 (μg/mL)      |
| WT Ala91Val     | 13.29 ± 1.40            | 10.50 ± 1.32     |
| Asp95Gly        | 13.29 ± 1.40            | >320             |

*IC50, half of maximal inhibitory concentrations; CC25, FQ concentrations required to induce 25% of DNA cleavage; CIP, ciprofloxacin; MOX, moxifloxacin; LVX, levofloxacin.*
The amino acid substitution of GyrA subunits at Ala91Val and Asp95Gly showed reduced sensitivity to all FQs, and more markedly than for WT DNA gyrase (2.19 to 14.65 μg/mL) (Fig. 5 and 6 and Table 2). MOX exhibited the highest inhibitory activity against *M. ulcerans* GyrA mutants among FQs examined in this study. The IC50 values of CIP, MOX, and LVX were over 20-fold higher against *M. ulcerans* shinshuense DNA gyrase mutants than those for WT DNA gyrase (Fig. 5 and Table 2). Similar results were observed for *M. ulcerans* Agy99 GyrA mutants (Fig. 5 and Table 2) and this may be related to its amino acid sequence homology (95%) to the *M. ulcerans* shinshuense GyrA subunit (unpublished data). Furthermore, to examine the effects of quinolone on cleavage complex formation by *M. ulcerans* recombinant DNA gyrases were performed that a similar tendency was observed in the DNA cleavage activities, CC25 was over 20-fold higher than for the WT DNA gyrase (Fig. 6 and Table 2). The observations suggested the contribution of amino acid substitutions Ala91Val and Asp95Gly in the GyrA subunit resulted in reduced sensitivity to FQs.

The structure-activity relationship between WT/mutant DNA gyrases and FQs was analyzed by molecular docking using MOE software (Fig. 7) to predict whether the GyrA subunit is associated with FQ resistance. A prediction of the three-dimensional (3D) structure of *M. ulcerans* shinshuense GyrA subunit was generated for structure-binding analysis with FQs because the crystal structure has not been reported. The WT or mutant *M. ulcerans* shinshuense GyrA subunit was modeled by Swiss-Model (https://swissmodel.expasy.org) using PDB 3IFZ (36) and 6RKS (37) as the templates (Fig. 7). The position of amino acid residues Ala91, Asp95, and Thr96 in WT GyrA interacted with that of the R3, R1, and R7 ring of CIP, respectively (Fig. 7A), which is suggested to contribute to potent inhibitory activity against *M. ulcerans* WT DNA gyrase (IC50 of 11.80 μg/mL). Modeling showed that CIP tightly binds to the quinolone-binding site on the GyrA subunit through hydrogen bonding interactions CH3–COO [R3], COO–CH2 [R1], and OH–CH2 [R7] (Fig. 7A left panel and Table 2). In contrast, the amino acid substitution of Asp95 to Gly on the GyrA subunit leads to a significant reduction in interaction with CIP (IC50 >320 μg/mL). This is primarily due to the disruption of the hydrogen bond interaction (Fig. 7A and Table 2), which induces extensive conformational changes in the quinolone-binding
s  i  t  e  a  n  d  a  b  r  o  g  a  t  e  s  t  h  e  e  n  z  y  m  e  a  c  t  i  v  i  t  y .  C  o  n  s  e  q  u  e  n  t  l  y ,  I  C  5 0  of  the  Asp95Gly  mutant  was  found to  be  higher  than  those of  the  WT and  Ala91Val  mutant (IC50 of 319.5 \( \mu g/mL \)).  Modeling  of the MOX ligand  in place of CIP showed similar  interactions (Fig. 7B).  In summary,  the two mutated  amino acids (Ala91Val  or Asp95Gly) likely  play important  roles in  causing reduced sensitivity  to FQ through altering  the hydrogen bonding network in  \( M.\)  ulcerans DNA gyrase.

In conclusion, in this  study, Ala91Val and Asp95Gly amino acid substitutions  in  \( M.\)  ulcerans DNA gyrase reduced  sensitivity to FQs \( \text{in vitro} \).  The present  findings will  aid in the design and development of novel \( \text{Bu}_{12} \) antibiotics  against the possible future emergence of FQ-resistant \( M.\) ulcerans carrying GyrA with these amino acid substitutions.

**MATERIALS AND METHODS**

**Materials.** CIP, LVX (LKT Laboratory, Inc., MN, USA), and MOX (Toronto Research Chemicals Inc.) were used for FQ inhibition assays, while ampicillin (Wako Pure Chemicals Ltd., Tokyo, Japan) was used for culturing \( E.\) coli harboring plasmids. Oligonucleotides were synthesized by Eurofins Genomics Inc. (Tokyo, Japan). A TOPO TA cloning kit (PCR 4-TOPO) was purchased from Life Technologies (Carlsbad, CA, USA) and used for cloning and nucleotide sequencing. DNA electrophoresis chemicals and restriction endonucleases were obtained from New England BioLabs, Inc. (Ipswich, MA, USA). Relaxed pBR322 DNA was purchased from John Innes Enterprises Ltd. (Norwich, United Kingdom). Protease inhibitor cocktail (Complete Mini, EDTA-free) was purchased from Roche Applied Science (Mannheim, Germany).

**Bacterial strains and plasmids.** Genomic DNA from the \( M.\) ulcerans shinshuense (28) and Agy99 strains (27) was gifted from Yuji Miyamoto, Leprosy Research Center, National Institute of Infectious Diseases (Tokyo, Japan). \( E.\) coli Top 10 and DH5\( \alpha \) strains were used as hosts for molecular cloning. The pColdI vector (TaKaRa Bio Inc., Shiga, Japan) was used to construct an expression vector to produce WT and mutant versions of recombinant GyrA and GyrB proteins from \( M.\) ulcerans shinshuense and Agy99 strains. \( E.\) coli BL21(DE3) (Merck KGaA, Darmstadt, Germany) was used for protein expression.

**Construction of WT gyrA and B expression plasmids.** WT gyrA and gyrB genes were amplified from genomic DNA of \( M.\) ulcerans shinshuense and Agy99 strain via PCR. The reaction mixtures (20 \( \mu L \)) contained 10\% LA PCR buffer II (Mg\( ^{2+}\)-free), 2.5 mM dNTP mixture, 2.5 mM MgCl\(_2\), 250 ng genomic DNA from \( M.\) ulcerans shinshuense or Agy99 strains, 1.25 units of LA Toq polymerase (TaKaRa Bio Inc.), and 0.1 \( \mu M \) each primer. The primer details are listed in Table 1. PCR was conducted using a TaKaRa PCR thermal cycler Dice mini (TaKaRa Bio Inc.) as follows: denaturation at 98°C for 2 min, 35 cycles of denaturation at
98°C for 10 s, annealing at 60°C for 10 s, and extension at 72°C for 3 min 30 s, with a final extension at 72°C for 2 min. The PCR products corresponding to the 2.5-kb gyrA and 2.1-kb gyrB fragments were ligated into the TA cloning plasmid, transformed into E. coli Top 10 and plated onto Luria-Bertani (LB) agar containing ampicillin (100 μg/mL). Colonies were selected, and plasmids were purified using a Miniprep DNA purification kit (Promega Madison, WI, USA), followed by digestion with NdeI and XhoI (for gyrA)/HindIII (for gyrB). The gyrA and gyrB fragments were ligated into the pCold-I expression vector restriction digested with the same restriction endonucleases. Mutant *M. ulcerans* DNA gyrase (Aal9Val or Asp95Gly) were generated from WT gyrA and gyrB using a QuikChange site-directed mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer’s instructions using the primers stated in Table 1. Plasmids were purified using a Miniprep DNA purification kit. WT and mutant plasmids were confirmed by sequencing (GENEWIZ corp., Tokyo, Japan) and were checked for errors by comparing to their respective WT and mutant sequences using BioEdit software (7.0.5.3).

**One expression and purification of recombinant M. ulcerans DNA gyrase subunits.** Recombinant DNA gyrase subunits were purified as previously described (38–40) with minor modifications. Briefly, the recombinant WT and mutant *M. ulcerans* gyrA and gyrB expression vectors were transformed into *E. coli* BL21(DE3) cells. Single colonies were picked and grown overnight at 37°C in 4 mL of LB medium containing 100 μg/mL ampicillin. Overnight cultures were used to inoculate 400 mL of fresh LB medium with ampicillin. Cells were cultured at 37°C for 7 to 8 h until the optical density (OD) at 600 nm reached 0.6 to 0.8, followed by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (Wako Pure Chemicals Ltd.) to induce protein expression and incubated at 14°C for 18 h. Cells were harvested by centrifugation at 13,000 × g for 20 min at 4°C and stored at −80°C for 12 h. Frozen cell pellets were resuspended in 20 mL ice-cold Talon binding buffer (50 mM sodium phosphate pH 7.4 and 300 mM NaCl) containing an EDA-free protease inhibitor cocktail, and disrupted with a UP50H sonicator (Hielscher Ultrasonic, Teltow, Germany) using 10 cycles (40 s on/60 s off) at 80% pulsar power on the ice. The lysate was centrifuged at 9,400 × g at 4°C for 20 min and the supernatant was applied onto a 5 mL His-Trap TALON crude column (GE Healthcare Bioscience, Piscataway, NJ, USA) pre-equilibrated with deionized water and Talon binding buffer. After sample application, the column was washed with Talon wash buffer (50 mM sodium phosphate pH 7.4, 300 mM NaCl, and 5 mM imidazole) until they reached a steady baseline. Proteins were eluted using Talon elution buffer (50 mM sodium phosphate pH 7.4, 300 mM NaCl, and 150 mM imidazole). The eluted proteins were concentrated using an Amicon Ultra-15 centrifugal filter unit (Millipore, Billerica, MA, USA) at 4,830 × g at 4°C for 15 min. WT and mutant DNA gyrases were further purified by gel filtration chromatography (ÄKTA pure, GE Healthcare Bioscience) using a Hi-Load 16/600 Superdex 200 prep grade column (GE Healthcare Bioscience) equilibrated with 20 mM Tris-Cl (pH 8.0) to remove imidazole. The eluted peaks of the same samples (280 nm) were assayed using supercoiling assays and analyzed using SDS-PAGE. Protein concentrations were determined using a Qubit assay kit (Thermo Fisher Scientific, Waltham, MA, USA).

**DNA gyrase activities and inhibition by FQs.** DNA supercoiling activity was determined using a combination of purified recombinant *M. ulcerans* GyrA and GyrB subunits as previously described (38–40). The reaction mixture (30 μL) consisted of supercoiling assay buffer (35 mM Tris-HCl pH 7.5, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM spermidine, 6 mM ATP, 0.1 mg/mL BSA, 6.5% wt/vol glycerol) and relaxed pBR322 DNA (0.3 μg) as the substrate. Assays were performed for 1 h at 30°C and stopped by the addition of 30 μL chloroform/iso-amyl alcohol (24/1) and 3 μL 10 × stop and loading solution (40% wt/vol sucrose, 100 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 μg/mL bromophenol blue). The product of the reaction was separated by electrophoresis using a 1% agarose gel with ethidium bromide (0.7 μg/mL). Supercoiling activity was quantified by measuring the band brightness of supercoiled pBR322 DNA using Image J 1.52a (http://rsbweb.nih.gov/ij). A concentration-dependent supercoiling assay using 1 to 24 μM GyrA or GyrB subunit was performed to determine the optimal concentration of each DNA gyrase subunit. The optimal temperature of WT *M. ulcerans* DNA gyrase supercoiling activity was measured at 20, 25, 30, 37, 40, and 50°C using the same concentrations as stated above and the optimal DNA gyrase subunit concentrations. Inhibition of *M. ulcerans* DNA gyrase supercoiling activity by FQs followed previous methods (38–40) with minor modifications. Briefly, reaction mixtures containing optimal DNA gyrase subunits and increasing FQ concentrations (0 to 320 μg/mL) were assayed as described above. The inhibitory effects of FQs on DNA gyrase activity were assessed by determining the drug concentration required to inhibit the supercoiling activity by 50% (IC50) using R studio free software version 1.4.1717. All assays were carried out at least three times and processed on the same day under identical conditions. To facilitate direct comparison, all incubations with WT and mutant DNA gyrase were carried out and processed in parallel on the same day under identical conditions, and assays were done at least three times, with reproducible results. Furthermore, to determine the more detailed functional role of *M. ulcerans* DNA gyrase, we performed FQs mediated DNA cleavage assays following previous methods (33, 41). Supercoiled pBR322 DNA (0.1 μg) was used as the substrate for DNA cleavage assays, and linearized pBR322 DNA by HindIII digestion was used as a marker for cleaved DNA. The quinolone concentrations required to induce 25% of the maximum DNA cleavage (CC25) were determined for CIP, MOX, and LVX.

**Predicted binding mode between DNA gyrase and FQs by molecular docking.** Molecular docking studies and visualization were conducted in the Molecular Operating Environment (MOE 2020.09, Chemical Computing Group ULC, Montreal, QC, Canada; https://www.chemcomp.com/index.htm). The docking model was designed using Swiss-Model (https://swissmodel.expasy.org). FQ coordinates were sketched using ChemBioDraw software (PerkinElmer, Waltham, MA, USA), and the amino acid substitutions were generated using the MOE-Protein builder module. Double-stranded oligonucleotides were adopted from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB ID: 6RKS) (37) because our docking model was not included in the double-strand oligonucleotide. Modified docking models were prepared using a...
flexible docking method with the scores expressed as a sum of five potentials: accessible surface area, Coulomb potential, hydrogen bonds, anisotropy, and van der Waals interactions and refined by MOE through energy minimization. The DNA gyrase and FQ binding energies were estimated using the Amber10 EHT force field and the implicit solvent model of the reaction field was selected. The best binding models were selected for the lowest free energies and optimized RMSD refinement. The distance between amino acid residues on GyrA and the side chain of FQs was calculated using WinCoot v0.9.4 (https://bernhardcl.github.io/coot/), and molecular graphics were generated using PyMOL v1.8 (https://pymol.org/2/).

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.9 MB

ACKNOWLEDGMENTS
We thank Yuji Miyamoto (Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Japan) for providing the M. ulcerans cDNA used in this study.

This study was supported partially by funds no. 21fk0108139j2302, JP18fk0108064, JP18fm0108008, JP18fk0108042, JP18jk0210005, and JP18jink0510001 from the Japan Agency for Medical Research and Development (AMED), partially by a Grant-in-Aid for Young Scientists (B) from the Japan Society for Promotion of Science (grant no. 17K15695), a grant from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

We declare no conflict of interest.

REFERENCES

1. WHO. 2000. Buruli Ulcer; Mycobacterium ulcerans infection. World Health Organization WHO/CDS/CPE/GBUI/2000.1.
2. Johnson PD, Stinear T, Small PL, Pluschke G, Merritt RW, Portaels F, Huygen K, Hayman JA, Asiedu K. 2005. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2:e108. https://doi.org/10.1371/journal.pmed.0020108.
3. Velink A, Wooley RJ, Phillips RO, Assamku K, van der Werf TS, Asamkhyen J, de Zeeuw J, Kils S, Stienstra Y. 2016. Former Buruli Ulcer Patients’ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management. PLoS Negl Trop Dis 10:e0005261. https://doi.org/10.1371/journal.pntd.0005261.
4. WHO. 2013. Sustaining the drive to overcome the global impact of neglected tropical diseases. World Health Organization ISBN 9789241564540.
5. Yotsu RR, Murase C, Sugawara M, Suzuki K, Nakanaga K, Ishii N, Asiedu K. 2015. Revisiting Buruli ulcer. J Dermatol 42:1033–1041. https://doi.org/10.1111/1680-0036.13049.
6. Amofah G, Bonsu F, Tetteh C, Okrah J, Asamoa K, Asiedu K, Addy J. 2002. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 8:167–170. https://doi.org/10.3201/eid0802.010119.
7. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Guedenon A, Scott JT, Dramaix M, Portaels F. 2004. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997–2001. Emerg Infect Dis 10:1391–1398. https://doi.org/10.3201/eid1008.030886.
8. Junghans T, Umu Boock A, Vogel M, Schuette D, Weinlaeder H, Plaschke G. 2009. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 3:e430. https://doi.org/10.1371/journal.pntd.0000430.
9. WHO. 2004. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization WHO/CDS/CPE/GBUI/2004.10.
10. Amofah GK, Sagoe-Moses C, Adeji-Acquah C, Frimpong EH. 1993. Epidemiology of Buruli ulcer in Amansie West district, Ghana. Trans R Soc Trop Med Hyg 87:644–645. https://doi.org/10.1046/j.1365-3109.93.090272.x.
11. Lufts M, Tay EL, Gobon M, Lavender CJ, Crouch SR, Johnson PDR, Fyfe JAM. 2018. Epidemiology of Buruli Ulcer Infections, Victoria, Australia, 2011–2016. Emerg Infect Dis 24:1988–1997. https://doi.org/10.3201/eid2411.171593.
12. Fast M, Diallo MO, Horsburgh CR, Jr., Diomande I, Saki MZ, Kangia JM, Patrice G, Lipman HB, Ostroff SM, Good RC. 1995. Emergence of Buruli ulcer disease in the Daloa region of Cote d’Ivoire. Am J Trop Med Hyg 52:219–224. https://doi.org/10.4269/ajtmh.1995.52.219.
13. Wallace JR, Mangas KM, Porter JL, Marcisiu R, Pidot SJ, Howden B, Omanse TF, Zeng W, Axford JK, Johnson PDR, Stinear TP. 2017. Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer. PLoS Negl Trop Dis 11:e0005553. https://doi.org/10.1371/journal.pntd.0005553.
14. van der Werf TS, Stinear T, Stienstra Y, van der Graaf WT, Small PL. 2003. Mycolactones and Mycobacterium ulcerans disease. Lancet 362:1062–1064. https://doi.org/10.1016/S0140-6736(03)14471-0.
15. Chauzy A, Ardant M-Foise, Adeye A, Euveete H, Guédénon A, Johnson C, Aubry J, Naumerberger E, Grosset J. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51:4029–4035. https://doi.org/10.1128/AAC.00175-07.
16. Dhople AM, Namba K. 2002. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. J Chemther 4:727–729. https://doi.org/10.1093/jac/dkf218.
17. Etuafui S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klutse E, Owusu-Boateng J, Amedofo GK, Awoah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49:3182–3186. https://doi.org/10.1128/AAC.01598-05.
18. O’Brien DP, McDonald A, Callan P, Robson M, Friedman ND, Hughes A, Holten I, Walton A, Athan E. 2012. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans. J Antimicrob Chemother 50:727–729. https://doi.org/10.1093/jac/dkt218.
19. Vincent QB, Ardant MF, Adeye A, Goundote A, Saint-Andre JP, Cottin J, Kempf M, Agossadou J, Johnson C, Abel L, Marsollier L, Chauty A, Alcais A. 2014. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. Lancet Glob Health 2:e422–e430. https://doi.org/10.1016/S2214-109X(14)70023-2.
20. Thangaraj HS, Adeji O, Allen BW, Portaels F, Evans MR, Banerjee DK, Wansbrough-Jones MH. 2000. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 45:231–233. https://doi.org/10.1093/jac/dkg218.
21. Bentouchea A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium
ulcerans infection in mice. Antimicrob Agents Chemother 45:3109–3112. https://doi.org/10.1128/AAC.45.11.3109-3112.2001.

22. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V. 2006. In vitro and in vivo activities of rifampin, streptomycin, amikacin, mofloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50:1921–1926. https://doi.org/10.1128/AAC.00052-06.

23. Vos SM, Tretter EM, Schmidt BH, Berger JM. 2011. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12:827–841. https://doi.org/10.1038/nrm3228.

24. Bush NG, Evans-Roberts K, Maxwell A. 2015. DNA Topoisomerases. EcoSal Plus 6. https://doi.org/10.1128/ecosalplus.ESP-0010-2014.

25. Pommier Y, Leo E, Zhang H, Marchand C. 2010. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17: 421–433. https://doi.org/10.1016/j.chembiol.2010.04.012.

26. Collin F, Karkare S, Maxwell A. 2011. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92: 479–497. https://doi.org/10.1007/s00253-011-3557-z.

27. Stinear TP, Seemann T, Pidot S, Frigui W, Reysset G, Garnier T, Meurice G, Simon D, Bouchier C, Ma L, Tichit M, Porter JL, Ryan J, Johnson PD, Davies JK, Jenkin GA, Small PL, Jones LM, Tekaia F, Daffe M, Parkhill J, Cole ST. 2007. Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res 17:192–200. https://doi.org/10.1101/gr.5942807.

28. Yoshida M, Nakanaga K, Otsu RR, Makino M, Ishii N. 2011. Nineteen cases of Buruli ulcer diagnosed in Japan from 1980 to 2010. J Clin Microbiol 49:1038–1040. https://doi.org/10.1128/JCM.00783-11.

29. Champoux JJ. 2001. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413. https://doi.org/10.1146/annurev.biochem.70.1.369.

30. Bates AD, Maxwell A. 2007. Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochemistry 46:7929–7941. https://doi.org/10.1021/bi700789g.

31. Nollmann M, Crisona NJ, Arimondo PB. 2007. Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie 89:490–499. https://doi.org/10.1016/j.biochi.2007.02.012.

32. Aubry A, Veziris N, Cambau E, Truffer-Penot C, Jarlier V, Fisher LM. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104–112. https://doi.org/10.1128/AAC.50.1.104-112.2006.

33. Ma X, Zheng B, Wang J, Li G, Cao S, Wen Y, Huang X, Zuo Z, Zhong Z, Gu Y. 2021. Quinolone Resistance of Actinobacillus pleuropneumoniae Revealed through Genome and Transcriptome Analyses. Int J Mol Sci 22: 10036. https://doi.org/10.3390/ijms221810036.

34. Kim H, Nakajima C, Kim YU, Yokoyama K, Suzuki Y. 2012. Influence of lineage-specific amino acid dimorphisms in GyrA on Mycobacterium tuberculosis resistance to fluoroquinolones. Jpn J Infect Dis 65:72–74.

35. Takiff HE, Salazar L, Guererro C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR, Jr., Tetenli A. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38:773–780. https://doi.org/10.1128/AAC.38.4.773.

36. Piton J, Petrelia S, Delarue M, Andre-Leroux G, Jarlier V, Aubry A, Mayer C. 2010. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 5:e12245. https://doi.org/10.1371/journal.pone.0012245.

37. Vanden Broeck A, Lotz C, Ortz J, Lamour V. 2019. Cryo-EM structure of the complete E. coli DNA gyrase nucleoprotein complex. Nat Commun 10:4935. https://doi.org/10.1038/s41467-019-12914-y.

38. Kim H, Nakajima C, Yokoyama K, Rahim Z, Kim YU, Oguri H, Suzuki Y. 2011. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob Agents Chemother 55:3661–3667. https://doi.org/10.1128/AAC.00442-11.

39. Yokoyama K, Kim H, Mukai T, Matsuoka M, Nakajima C, Suzuki Y. 2012. Amino acid substitutions at position 95 in GyrA can add fluoroquinolone resistance to Mycobacterium leprae. Antimicrob Agents Chemother 56:697–702. https://doi.org/10.1128/AAC.05890-11.

40. Kim H, Fukutomi Y, Nakajima C, Kim YU, Mori S, Shibayama K, Nakata N, Suzuki Y. 2019. DNA gyrase could be a crucial regulatory factor for growth and survival of Mycobacterium leprae. Sci Rep 9:10815. https://doi.org/10.1038/s41598-019-47364-5.

41. Nakanaga K, Hoshino Y, Yotsu RR, Makino M, Ishii N. 2011. Nineteen cases of Buruli ulcer diagnosed in Japan from 1980 to 2010. J Clin Microbiol 49: 3829–3836. https://doi.org/10.1128/JCM.00783-11.